Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies

Scandinavian Cardiovascular Journal

Volumn 43, Issue 6, 2009, Pages 395-401

  Paakkanen, Riitta ^a,b   Palikhe, Anil ^a,b   Seppänen, Mikko ^a   Nieminen, Markku S ^a   Vauhkonen, Hanna ^b   Saikku, Pekka ^c   Lokki, Marja Liisa ^b   Sinisalo, Juha ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Acute coronary syndrome; Antibiotic therapy; Chlamydia pneumoniae; Complement C4 deficiency; Coronary artery disease; Mortality; Pharmacogenomics

Indexed keywords

CLARITHROMYCIN; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; ALLOTYPE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLEMENT DEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SECONDARY PREVENTION; STROKE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA PNEUMONIAE; CLARITHROMYCIN; COMPLEMENT C4; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 72049097142     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430902874305     Document Type: Article

References (33)

1. Arason GJ, Kramer J, Bodvarsson S, Sigurdarson ST, Sigurdsson G, Fust G, et al. Increased frequency of C4B null alleles in Icelandic patients with coronary artery disease. Mol Immunol. 1998;/35:/412.
2. Blasko B, Kolka R, Thorbjornsdottir P, Sigurdarson ST, Sigurdsson G, Ronai Z, et al. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction. Int Immunol. 2008;/20:/31-7.
3. Kramer J, Rajczy K, Hegyi L, Fulop T, Mohacsi A, Mezei Z, et al. C4B*Q0 allotype as risk factor for myocardial infarction. BMJ. 1994;/309:/313-4.
4. Porto I, Leone AM, Crea F, Andreotti F. Inflammation, genetics, and ischemic heart disease: Focus on the major histocompatibility complex (MHC) genes. Cytokine. 2005;/ 29:/187-96.
5. Wang Q. Molecular genetics of coronary artery disease. Curr Opin Cardiol. 2005;/20:/182-8. (Pubitemid 40704874)
6. Blanchong CA, Chung EK, Rupert KL, Yang Y, Yang Z, Zhou B, et al. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol. 2001;/1:/365-92.
7. Samano ES, Ribeiro Lde M, Gorescu RG, Rocha KC, Grumach AS. Involvement of C4 allotypes in the pathogenesis of human diseases. Rev Hosp Clin Fac Med Sao Paulo. 2004;/59:/138-44.
8. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 2006;/6:/ 508-519
9. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 1993;/14(Suppl K):/12-6. (Pubitemid 24038946)
10. Seppanen M, Lokki ML, Notkola IL, Mattila K, Valtonen V, Nieminen A, et al. Complement and c4 null alleles in severe chronic adult periodontitis. Scand J Immunol. 2007;/65:/ 176-181
11. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis. 2002;/2:/11-7.
12. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A meta-analysis of randomized controlled trials. JAMA. 2005;/ 293:/2641-7.
13. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Pravastatin or atorvastatin E, infection therapy-thrombolysis in myocardial infarction I. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;/352:/1646-54.
14. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Investigators in the WS. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: A randomized controlled trial. JAMA. 2003;/290:/1459-66.
15. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J. 1999;/20:/121-7.
16. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Clarithromycin in Acute Coronary Syndrome Patients in Finland Study G. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation. 2002;/105:/1555-60.
17. Seppanen M, Suvilehto J, Lokki ML, Notkola IL, Jarvinen A, Jarva H, et al. Immunoglobulins and complement factor C4 in adult rhinosinusitis. Clin Exp Immunol. 2006;/145:/219-27.
18. Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Fust G, et al. Diversity in intrinsic strengths of the human complement system: Serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol. 2003;/171:/2734-45.
19. Sim E, Cross SJ. Phenotyping of human complement component C4, a class-III HLA antigen. Biochem J. 1986;/ 239:/763-7.
20. Marcus D, Alper CA. Methods for allotypeing complement proteins. In: Rose NR, Friedman H and Fahey JL, ed. Manual of clinical laboratory immunology. American Society for Microbiology; 1986. p 185-196.
21. Palikhe A, Sinisalo J, Seppanen M, Valtonen V, Nieminen MS, Lokki ML. Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease. Tissue Antigens. 2007;/69:/47-55.
22. Seppanen M, Meri S, Notkola IL, Seppala IJ, Hiltunen-Back E, Sarvas H, et al. Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia. J Infect Dis. 2006;/194:/571-8.
23. Dupont WD, Plummer WD, Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;/19:/589-601.
24. Szalai C, Fust G, Duba J, Kramer J, Romics L, Prohaszka Z, et al. Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. J Med Genet. 2002;/39:/ 46-51.
25. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;/99:/890-5.
26. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001;/103:/45-51.
27. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: A class of potent immunomodulators. Int J Antimicrob Agents. 2008;/31:/12-20.
28. Palikhe A, Lokki ML, Saikku P, Leinonen M, Paldanius M, Seppanen M, et al. Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease. Clin Vaccine Immunol. 2008;/15:/55-9.
29. Puolakkainen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Seroepidemiological response to C. pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 1993;/31:/2212-4.
30. Aittoniemi J, Fan YM, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, et al. The effect of mannan-binding lectin variant alleles on coronary artery reactivity in healthy young men. Int J Cardiol. 2004;/97:/317-8.
31. Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjoholm AG. Hereditary C2 deficiency in Sweden: Frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore). 2005;/84:/ 23-34.
32. Paju S, Sinisalo J, Pussinen PJ, Valtonen V, Nieminen MS. Is periodontal infection behind the failure of antibiotics to prevent coronary events? Atherosclerosis. 2007;/193:/193-5.
33. Seppänen M, Lokki ML, Notkola I-L, Mattila K, Valtonen V, Nieminen A, et al. Complement and C4 null alleles in severe chronic adult periodontitis. Scand J Immunol. 2007;/65:/ 176-181